Federal watchdog will review the controversial FDA approval of Biogen’s Alzheimer’s drug

The federal watchdog at the Department of Health and Human Services will review the process used by the Food and Drug Administration to approve the Alzheimer’s drug sold by Biogen, which has caused unprecedented controversy over regulatory standards.